Protagonist Therapeutics (PTGX) reported Q4 earnings Friday of $1.98 per diluted share, up from $0.44 a year earlier.

License and collaboration revenue for the quarter ended Dec. 31 was $170.6 million, compared with $60 million a year earlier.

The company said it expects its cash, cash equivalents and marketable securities of $559.2 million as of Dec. 31 to provide cash runway through the end of 2028.

Shares of the company were up more than 4% in recent premarket activity.